Research - Update: On November 11, Viropharma was purchased by Shire Pharma for $4.2B. The acquisition netted PropThink readers who bought alongside us saw a 100% return … Continue Reading
Read NowResearch - Keryx Biopharmaceuticals (KERX) announced on Tuesday that a phase 2 study of Zerenex (ferric citrate) in non-dialysis dependent chronic kidney disease (CKD) patients with elevated … Continue Reading
Read NowLong Ideas - Early this year, Keryx Biopharmaceuticals (KERX) reported strong Phase III results for its phosphate binder Zerenex (ferric citrate) in dialysis patients, sending the stock from … Continue Reading
Read NowLong Ideas - 2013 has been a banner year for biotech IPO’s, with a number of companies making their public debuts to strong reception by the market. BIND … Continue Reading
Read NowLong Ideas - On October 3, 2013, PropThink hosted an interview and investor Q&A with Tekmira Pharmaceuticals’ (TKMR) CEO Dr. Mark Murray. A recording and transcript of that … Continue Reading
Read NowLong Ideas - PropThink has been bullish on Questcor Pharmaceuticals (QCOR) for quite some time, and since our report highlighting the company’s prospects late last year, shares have … Continue Reading
Read NowLong Ideas - Targeted therapies are the oncologists’ precision tool in treating difficult cancers. Where early therapeutics like radiotherapy and chemotherapy tackle cancers by bombarding all rapidly dividing … Continue Reading
Read Now
